Skip to main content

Dr. Michael Morris, MD

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
32
In the NPI registry since
2006
Medicare patients seen, 2024
163

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1994Medical school: Icahn School of Medicine at Mount Sinai
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    NY license 202032

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
163
Services billed
522
Patients’ average age
77
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 20-29 minutes190107
Established patient office or other outpatient visit, 30-39 minutes14278
New patient office or other outpatient visit, 60-74 minutes2727
Established patient office or other outpatient visit, 40-54 minutes1512

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Nubeqa (darolutamide)120
Prednisone
Other prescribers in New York, NY
98
Xtandi (enzalutamide)87
Abiraterone Acetate72
Orgovyx (relugolix)65
Erleada (apalutamide)22
Alendronate Sodium
Other prescribers in New York, NY
16
Tamsulosin Hcl
Other prescribers in New York, NY
13
Zytiga (abiraterone acetate)12

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 7 companies reported 36 payments worth $26,093 in total to this clinician.

By company
E.r. Squibb & Sons, L.l.c.$14,453
AbbVie Inc.$7,958
GlaxoSmithKline, LLC.$2,400
Janssen Global Services, LLC$547
Amgen Inc.$373
Progenics Pharmaceuticals, Inc.$265
AstraZeneca Pharmaceuticals LP$97.00
By type
Consulting Fee$21,089
Travel and Lodging$3,797
Food and Beverage$1,207

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Oct 20, 2025E.r. Squibb & Sons, L.l.c.
Oct 20, 2025
Consulting Fee$12,889
Dec 8, 2025AbbVie Inc.
Dec 8, 2025
Consulting Fee$5,800
Apr 2, 2025GlaxoSmithKline, LLC.
Apr 2, 2025
Consulting Fee$2,400
Sep 22, 2025Janssen Global Services, LLC
Sep 22, 2025
Travel and Lodging
travel to NEW BRUNSWICK, NJ · in-kind
$533
Nov 9, 2025AbbVie Inc.
Nov 9, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionM24-742
$509
Sep 2, 2025E.r. Squibb & Sons, L.l.c.
Sep 2, 2025
Travel and Lodging
travel to Boston, MA
$387
Sep 3, 2025E.r. Squibb & Sons, L.l.c.
Sep 3, 2025
Travel and Lodging
travel to Boston, MA
$387
Nov 8, 2025AbbVie Inc.
Nov 8, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionM24-742
$281
Nov 9, 2025AbbVie Inc.
Nov 9, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionM24-742
$281
Nov 10, 2025AbbVie Inc.
Nov 10, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionM24-742
$281
All 19 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 8, 2025AbbVie Inc.
Dec 8, 2025
Consulting Fee$5,800
Dec 8, 2025AbbVie Inc.
Dec 8, 2025
Travel and Lodging
travel to NEW YORK, NY · in-kind
$158
Nov 10, 2025AbbVie Inc.
Nov 10, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionM24-742
$281
Nov 9, 2025AbbVie Inc.
Nov 9, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionM24-742
$509
Nov 9, 2025AbbVie Inc.
Nov 9, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionM24-742
$281
Nov 9, 2025AbbVie Inc.
Nov 9, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionM24-742
$92.28
Nov 8, 2025AbbVie Inc.
Nov 8, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionM24-742
$281
Nov 8, 2025AbbVie Inc.
Nov 8, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionM24-742
$198
Oct 28, 2025E.r. Squibb & Sons, L.l.c.
Oct 28, 2025
Travel and Lodging
travel to BOSTON, MA
$165
Oct 20, 2025E.r. Squibb & Sons, L.l.c.
Oct 20, 2025
Consulting Fee$12,889
Sep 22, 2025Janssen Global Services, LLC
Sep 22, 2025
Travel and Lodging
travel to NEW BRUNSWICK, NJ · in-kind
$533
Sep 22, 2025Janssen Global Services, LLC
Sep 22, 2025
Travel and Lodging
travel to NEW YORK, NY · in-kind
$5.50
Sep 3, 2025E.r. Squibb & Sons, L.l.c.
Sep 3, 2025
Travel and Lodging
travel to Boston, MA
$387
Sep 3, 2025E.r. Squibb & Sons, L.l.c.
Sep 3, 2025
Travel and Lodging
travel to Boston, MA
$258
Sep 3, 2025E.r. Squibb & Sons, L.l.c.
Sep 3, 2025
Travel and Lodging
travel to Boston, MA
$37.74
Sep 3, 2025E.r. Squibb & Sons, L.l.c.
Sep 3, 2025
Travel and Lodging
travel to Boston, MA
$19.98
Sep 2, 2025E.r. Squibb & Sons, L.l.c.
Sep 2, 2025
Travel and Lodging
travel to Boston, MA
$387
Apr 2, 2025GlaxoSmithKline, LLC.
Apr 2, 2025
Consulting Fee$2,400
Jan 21, 2025Amgen Inc.
Jan 21, 2025
Travel and Lodging
travel to BARCELONA, Spain
$203

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New York →

Industry-funded research

Named as a principal investigator on 7 industry-funded studies in 2025, from 7 companies. The companies reported $4,955,296 in research payments for these studies, mostly to the institutions running them.

  • Collaboration Agreement - Prostate Cancer Clinical Trials Consortium, LLC, The (PCCT)
    Bayer HealthCare Pharmaceuticals Inc.
  • A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer
    Janssen Research & Development, LLC
  • A phase 1, open-label, functional imaging study to assess whether CC-90011 reverses the castration resistance due to lineage switch in participants with metastatic castration-resistant prostate cancer (mCRPC) who have…
    Celgene Corporation
  • A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
    Astellas Pharma Global Development
  • PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Re…
    Novartis Pharmaceuticals Corporation
  • A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With …
    Amgen Inc.
  • A phase 1, open-label, functional imaging study to assess whether CC-90011 reverses the castration resistance due to lineage switch in participants with metastatic castration-resistant prostate cancer (mCRPC) who have…
    E.r. Squibb & Sons, L.l.c.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in New York

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 6, 2015), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1255302055. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.